[ad_1] – In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine protein-to-creatinine ratio at Week […]
Tag: Renalys Pharma
Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology
[ad_1] TOKYO, Oct. 22, 2025 /PRNewswire/ — Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; “Renalys”) is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese Society […]
Sparsentan receives Orphan Drug Designation for primary IgA nephropathy in Japan
[ad_1] TOKYO, Dec. 2, 2024 /PRNewswire/ — Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. (“Travere”) and currently in phase III clinical trials in Japan, has received […]
